Research Analysts Offer Predictions for IDYA FY2024 Earnings

IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2024 EPS estimates for IDEAYA Biosciences in a research note issued to investors on Wednesday, October 16th. Cantor Fitzgerald analyst L. Watsek expects that the company will earn ($2.26) per share for the year. Cantor Fitzgerald has a "Overweight" rating on the stock. The consensus estimate for IDEAYA Biosciences' current full-year earnings is ($2.51) per share.

Several other analysts have also issued reports on the stock. Mizuho began coverage on shares of IDEAYA Biosciences in a research report on Monday, July 8th. They issued an "outperform" rating and a $50.00 target price on the stock. Citigroup reduced their target price on IDEAYA Biosciences from $60.00 to $58.00 and set a "buy" rating for the company in a report on Tuesday, August 27th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $61.00 price target on shares of IDEAYA Biosciences in a research note on Tuesday, September 24th. Stifel Nicolaus increased their price objective on IDEAYA Biosciences from $63.00 to $68.00 and gave the company a "buy" rating in a research note on Tuesday, September 10th. Finally, JPMorgan Chase & Co. lowered their target price on shares of IDEAYA Biosciences from $69.00 to $66.00 and set an "overweight" rating on the stock in a research note on Thursday, August 8th. Thirteen investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $56.00.

IDEAYA Biosciences Stock Down 0.5 %

Shares of IDYA stock traded down $0.15 during trading hours on Friday, hitting $30.54. 790,812 shares of the company's stock were exchanged, compared to its average volume of 856,827. The firm has a 50 day moving average of $34.94 and a two-hundred day moving average of $37.87. IDEAYA Biosciences has a fifty-two week low of $23.41 and a fifty-two week high of $47.74. The firm has a market cap of $2.31 billion, a P/E ratio of -15.19 and a beta of 0.82.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last released its quarterly earnings results on Tuesday, August 6th. The company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.54) by ($0.14). During the same quarter in the prior year, the business posted ($0.50) EPS.

Institutional Trading of IDEAYA Biosciences

Several hedge funds have recently made changes to their positions in the company. Wellington Management Group LLP purchased a new position in IDEAYA Biosciences in the fourth quarter worth approximately $2,988,000. Vanguard Group Inc. raised its holdings in IDEAYA Biosciences by 17.0% in the 4th quarter. Vanguard Group Inc. now owns 3,475,772 shares of the company's stock valued at $123,668,000 after buying an additional 504,275 shares during the period. JTC Employer Solutions Trustee Ltd acquired a new position in IDEAYA Biosciences in the first quarter valued at about $67,000. Principal Financial Group Inc. boosted its stake in IDEAYA Biosciences by 4.4% during the first quarter. Principal Financial Group Inc. now owns 15,275 shares of the company's stock worth $670,000 after buying an additional 648 shares during the period. Finally, Capstone Investment Advisors LLC boosted its stake in IDEAYA Biosciences by 7.1% during the first quarter. Capstone Investment Advisors LLC now owns 59,180 shares of the company's stock worth $2,597,000 after buying an additional 3,941 shares during the period. Hedge funds and other institutional investors own 98.29% of the company's stock.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.